Gilead Gets Buy, Amgen Holds: Biopharma Calls Roil Markets
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Marriage brings new financial dynamics, so knowing when to modify your budget is crucial for a harmonious financial partnership.
19,179 articlesWall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Software stocks are rebounding as growth signals improve and enterprise demand remains resilient. Analysts warn that ...
A fresh framework shows a simple trio of ETFs may match the glide-path goals of target-date funds for those planning ...
Institutional buyers stepped back into Bitcoin, lifting spot ETF inflows and signaling a shift back toward the market...
On July 10, 2026, ETH, XRP, ADA, BNB and HYPE navigate a choppy path as traders weigh resistance and support levels. ...
Oracle delivered a standout quarter, signaling AI investments and data-center expansion can pay off. The company rais...
A well-known trading app moving deeper into crypto and tokenized assets could reshape where traders park capital. Thi...
Analysts raise the oracle price target $240 after Oracle reports resilient AI cloud demand and stronger-than-expected...
Investors rewarded Meta Platforms after news suggesting a sharper AI-driven monetization strategy and resilient ad de...
Investors are eyeing CAVA as a potential hit in fast casual. This article weighs growth prospects, unit economics, an...
This analysis dives into the early 2026 earnings picture for J.Jill, unpacking revenue drivers, margin dynamics, and ...